Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin‐3 and granulocyte‐macrophage colony‐stimulating factor expression

Blank, Miri; George, Jacob; Fishman, Pnina; Levy, Yair; Toder, V.; Savion, Shoshana; Barak, Vivian; Koike, Takao; Shoenfeld, Yehuda

doi:10.1002/1529-0131(199802)41:2<224::aid-art6>3.3.co;2-n

Cited by 15 publications

(14 citation statements)

References 12 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The peptide sequences are found in many human viruses to which people are commonly exposed. Recently, Blank et al [53] demonstrated that ciprofloxacin, which has the ability to induce interleukin-3 production, can immunomodulate and benefit mice induced with the experimental APS.…”

Section: Catastrophic Aps and Infectionsupporting

confidence: 70%

The antiphospholipid syndrome and infection

2001

View full text Add to dashboard Cite

Infectious agents have been implicated in the induction of antiphospholipid (aPL) antibodies and the development of the antiphospholipid syndrome (APS). This review focuses on the types of aPL antibodies detected in infections and addresses whether these antibodies are of clinical importance in patients with infections. Hepatitis C virus (HCV) infection is given special attention because this virus has the propensity to induce various autoimmune phenomena. Several aspects are emphasized that should be considered carefully when interpreting results. Most of the published data agree that thrombophilia is not observed in patients with infections (including HCV) because aPL antibodies are mostly the natural or nonpathogenic type. Thus, we do not recommend routinely testing for HCV in patients with APS. However, not all infection-associated aPL antibodies are cofactor independent. For instance, infections are increasingly recognized as a major precipitating condition of the catastrophic variant of APS, perhaps via mechanisms of molecular mimicry. Therefore, it may be possible to prevent this devastating evolution if the infectious process is promptly recognized and exhaustively treated.

show abstract

Section: Catastrophic Aps and Infectionsupporting

confidence: 70%

The antiphospholipid syndrome and infection

2001

View full text Add to dashboard Cite

show abstract

“…Ciprofloxacin was found to reduce pregnancy loss in an animal model of APS via elevation of Il-3 and GM-CSF production [79][80][81][82]. These in vivo data are complementary to the in vitro studies demonstrating enhanced secretion of CSFs and in vivo studies proving enhanced hematopoiesis in immunocompromised animals.…”

Section: Non-antibacterial Effects Of Fqs In Experimental Animalsmentioning

confidence: 95%

Immunomodulatory Activities of Fluoroquinolones

2005

View full text Add to dashboard Cite

A review of published data on the in vitro, ex vivo, in vivo and clinical effects of fluoroquinolones on the synthesis of cytokines is provided. Fluoroquinolones (FQs) were found to affect both cellular and humoral immunity. In general, FQs exert their modulating effects only when used together with a co-stimulant. The in vitro studies generated heterogeneous data because of inhomogeneous effects triggered by different types of co-stimulants and differing responses of various cell lines on the stimuli. However, there is the general trend that FQs decrease the synthesis of pro-inflammatory cytokines. Studies in experimental animals generated homogenous data. All the FQs studied exerted significant clinical effects by attenuating cytokine responses in vivo. The FQs were found to be effective in vivo either in infections caused by organisms against which these are inactive or when dosed suboptimally, so that serum levels were lower than the susceptibilities of the causative pathogens. These in vivo effects were correlated with a significant decrease in pro-inflammatory cytokines like Il-1 and TNF. In addition, FQs were found to upregulate hematopoiesis. These immunomodulatory effects can be attributed in particular to those FQs with a cyclopropyl-moiety at the position N1 of the quinolone core structure, i. e. ciprofloxacin, moxifloxacin, grepafloxacin, sparfloxacin. The immunomodulatory effects of the FQs are due to their effects on intracellular cyclic AMP and phosphodiesterases, on transcription factors such as NF-kappa B, activator protein 1 and a triggering effect on the eucaryotic equivalent of bacterial SOS response. All these studies indicate that FQs exert immunomodulatory activities in particular in latent or chronic infections.

show abstract

“…Reports of APS abrogation following eradication of H. pylori (Cicconi et al, 2001) have emphasized the significance of the bacteria's continuous presence in the development of this autoimmune disease. In another study (Blank et al, 1998), ciprofloxacin treatment has been shown to improve the clinical manifestations of APS in an experimental APS model, by induction of interleukin-3 and granulocyte-monocyte colony-stimulating factor expression.…”

Section: Therapeutic Implicationsmentioning

confidence: 99%